| Revision as of 23:48, 26 August 2011 editZéroBot (talk | contribs)704,777 editsm r2.7.1) (robot Adding: hu:Linszidomin← Previous edit |
Latest revision as of 13:18, 10 July 2023 edit undoJJMC89 bot III (talk | contribs)Bots, Administrators3,685,221 editsm Moving Category:4-Morpholinyl compunds to Category:4-Morpholinyl compounds per Misplaced Pages:Categories for discussion/Speedy |
| (19 intermediate revisions by 19 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{drugbox |
|
|
|
{{Drugbox |
|
|
| Watchedfields = changed |
|
⚫ |
| verifiedrevid = 446899189 |
|
⚫ |
| IUPAC_name = 5-imino-3-morpholin-4-yl-5''H''-1,2,3-oxadiazol-3-ium-2-ide |
|
⚫ |
| image = Linsidomine structure.svg |
|
|
|
|
|
<!--Clinical data--> |
|
|
| tradename = |
|
|
| Drugs.com = {{drugs.com|international|linsidomine}} |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
⚫ |
| CAS_number = 33876-97-0 |
|
|
| CAS_supplemental = <br />{{CAS|16142-27-1}} (hydrochloride) |
|
⚫ |
| ATC_prefix = C01 |
|
⚫ |
| ATC_suffix = DX18 |
|
⚫ |
| PubChem = 5219 |
|
⚫ |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| UNII = 5O5U71P6VQ |
|
| UNII = 5O5U71P6VQ |
| ⚫ |
| verifiedrevid = 437150151 |
|
| ⚫ |
| IUPAC_name = 5-imino-3-morpholin-4-yl-5''H''-1,2,3-oxadiazol-3-ium-2-ide |
|
| ⚫ |
| image = Linsidomine.png |
|
|
| width = 120px |
|
| ⚫ |
| CAS_number = |
|
| ⚫ |
| ATC_prefix = C01 |
|
| ⚫ |
| ATC_suffix = DX18 |
|
| ⚫ |
| PubChem = 5219 |
|
| ⚫ |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| ⚫ |
| DrugBank = |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D07161 |
|
| KEGG = D07161 |
|
|
| synonyms = SIN-1 |
|
| C=6|H=10|N=4|O=2 |
|
|
|
| ChemSpiderID = 10561427 |
|
| molecular_weight = 170.17 g/mol |
|
|
|
|
| ⚫ |
| bioavailability = |
|
|
|
<!--Chemical data--> |
| ⚫ |
| protein_bound = |
|
|
| metabolism = |
|
| C=6 | H=10 | N=4 | O=2 |
|
|
| smiles = C1COCCN12=NOC(=C2) |
| ⚫ |
| elimination_half-life = |
|
|
|
| StdInChI = 1S/C6H10N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7H,1-4H2 |
| ⚫ |
| excretion = |
|
|
|
| StdInChIKey = FKDHHVKWGRFRTG-UHFFFAOYSA-N |
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
|
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= |
|
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| ⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| ⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
|
|
|
|
|
'''Linsidomine''' ('''3-morpholinosydnonimine''' or '''SIN-1'''<ref name="Wen-2005">{{cite journal | vauthors = Wen TC, Rogido MR, Moore JE, Genetta T, Peng H, Sola A | title = Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro | journal = Neuroscience Letters | volume = 387 | issue = 1 | pages = 38–42 | date = October 2005 | pmid = 16084018 | doi = 10.1016/j.neulet.2005.07.018 }}</ref>) is a ]. It is a metabolite of the antianginal drug ] and acts by releasing ] from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection<ref>{{cite journal | vauthors = Lemaire A, Buvat J | title = | journal = Progres en Urologie | volume = 8 | issue = 3 | pages = 388–91 | date = June 1998 | pmid = 9689672 }}</ref> in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.{{fact|date=January 2012}} |
|
'''Linsidomine''' is a ]. |
|
|
|
|
|
Linsidomine (SIN-1) is a metabolite of the antianginal drug ] and acts by releasing ] from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation ). Linsidomine injection at a dose of 1 mg produces usable erection in about 70% of patients and full erection in up to 50% of patients . Linsidomine does not appear to be associated with priapism . |
|
|
|
Linsidomine is neurotoxic and promotes ] on neurons.<ref name="Wallace-2006">{{cite journal | vauthors = Wallace DR, Dodson S, Nath A, Booze RM | title = Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function | journal = Synapse | volume = 59 | issue = 1 | pages = 51–60 | date = January 2006 | pmid = 16237680 | doi = 10.1002/syn.20214 }}</ref> Linsidomine is a ]-generating compound involved in the pathogenesis of ].<ref name="Jang-2004">{{cite journal | vauthors = Jang JH, Aruoma OI, Jen LS, Chung HY, Surh YJ | title = Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death | journal = Free Radical Biology & Medicine | volume = 36 | issue = 3 | pages = 288–99 | date = February 2004 | pmid = 15036348 | doi = 10.1016/j.freeradbiomed.2003.11.005 }}</ref> |
|
|
|
|
|
== References == |
|
|
{{Reflist}} |
|
|
|
|
|
{{Vasodilators used in cardiac diseases}} |
|
{{Vasodilators used in cardiac diseases}} |
|
|
{{Nitric oxide signaling}} |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
|
|
|
|
|
{{cardiovascular-drug-stub}} |
|
|
|
|
|
] |
|